Dosing regimen for Anti-DLL3 agent
TW202633916APending Publication Date: 2026-08-16AMGEN INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- TW114137585
- Authority / Receiving Office
- TW · TW
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-10-01
- Filing Date
- 2025-09-30
- Publication Date
- 2026-08-16
Smart Images
Figure TWG2TA001072654_001 
Figure TWG2TA001072654_002
Abstract
The disclosure relates to compositions and methods for treating DLL3-expressing cancers by administration of an anti-DLL3 antigen-binding agent (e.g., tarlatamab) to a subject once every four weeks (Q4W).
Need to check novelty before this filing date? Find Prior Art